Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MBP-Y005
- Development stage
- Preclinical
- Lead developer
- Mebiopharm
- Modality
- Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
MBP-Y005 is a preclinical-stage, transferrin-targeted nanoparticle drug delivery system developed by Mebiopharm. It utilizes a transferrin-conjugated liposome (Tf-liposome) technology designed to exploit the overexpression of transferrin receptors (TfR) on the surface of cancer cells. By binding to TfR, the nanoparticle is internalized via receptor-mediated endocytosis, allowing for the targeted delivery of its cytotoxic payload directly into tumor cells while minimizing systemic toxicity. Mebiopharm is developing MBP-Y005 for the treatment of solid tumors, including non-small cell lung cancer (NSCLC), pancreatic cancer, and biliary cancer.
02
Targets
TFRC (Transferrin Receptor)
Beyond the preview
Go deeper on MBP-Y005.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MBP-Y005.